Facebook
Twitter
LinkedIn
Forward
Advances in the Treatment of Tics
Live Webinar on June 10, 2021 at 3:00 PM ET
This webcast is hosted via the GoToWebinar platform
To register for this webcast on advances in the treatment of tics please click here
Motor and phonic tics associated with Tourette syndrome (TS) can range in severity from barely perceptible to disabling and most patients have a variety of behavioral co-morbidities, particularly, attention deficit disorder and obsessive-compulsive disorder. Therefore, therapy must be tailored to the individual needs of the patients. In addition to behavioral therapy, oral medications such as alpha agonists, dopamine depletors, anti-psychotics, and topiramate are used to control the involuntary movements and noises. Botulinum toxin injections are particularly effective in patients with troublesome focal motor and phonic tics, including coprolalia. Deep brain stimulation may be considered for patients with “malignant” TS, that is, refractory to medical therapy. When appropriate therapy is selected and implemented, most patients with TS can achieve their full potential and lead essentially normal life.
Target Audience
Physicians and Physician Specialists, Physician Assistants, Nurse Practitioners, Registered Nurses, Psychologists, Social Workers, Medical Students, Residents, Fellows and other allied healthcare professionals engaged in the care of patients with Tourette syndrome.
Learning Objectives
After participating in this webcast, participants should be better able to:
- Review the current therapeutic approach in patients with tics and Tourette syndrome.
- State the rationale for and basic pharmacology of novel drugs used in the treatment of Tourette syndrome.
- Identify emerging medical and surgical treatments of tics.
Faculty
Dr. Joseph Jankovic
Professor of Neurology
Distinguished Chair in Movement Disorders Director, Parkinson’s Disease Center and Movement Disorders Clinic Director
Center of Excellence for Parkinson’s Foundation and Tourette Association of America
Baylor College of Medicine
Dr. Jankovic is a Professor of Neurology, Distinguished Chair in Movement Disorders, and Founder and Director of the Parkinson’s Disease Center and Movement Disorders Clinic (PDCMDC), Department of Neurology, Baylor College of Medicine, Houston, Texas. After completing his Neurology training at Columbia University, New York City, he joined the faculty of Baylor College of Medicine in 1977. Since that time he has led clinical team that focuses on the most compassionate and expert care and research on etiology, pathophysiology, and experimental therapeutics of Parkinson’s disease and related neurodegenerative and movement disorders such as tremors, dystonia, Tourette syndrome, Huntington disease, restless legs syndrome, tardive dyskinesia, and paroxysmal dyskinesias. Under the direction of Dr. Jankovic the PDCMDC has been recognized as “Center of Excellence” by the Parkinson’s Foundation, the Huntington Disease Society of America, the Tourette Association of America, and the Wilson Disease Association.
Past president of the International Parkinson and Movement Disorder Society and of the International Neurotoxin Association, Dr. Jankovic is the recipient of many awards including the American Academy of Neurology (AAN) Movement Disorders Research Award, First National Parkinson Foundation Distinguished Service Award, Huntington’s Disease Society of America Guthrie Family Humanitarian Award, Tourette Syndrome Association Lifetime Achievement Award, Dystonia Medical Research Foundation Distinguished Service Award, Benign Essential Blepharospasm Research Foundation Award, and Lifetime Achievement Award from the International Neurotoxin Association, Dr. Jankovic has been recognized as an Honorary Member of the American Neurological Association, Australian Association of Neurologists, French Neurological Society, and the International Parkinson’s Disease and Movement Disorders Society.
Accreditation
Credit Designations:
Physicians: The Warren Alpert Medical School of Brown University designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants & Nurse Practitioners: Participants will receive a Certificate of Attendance stating this program is designated for 1.0 hours AMA PRA Category 1 Credit™. This credit is accepted by the AAPA and AANP.
How to Claim Credit
The webcast is viewed via the GoToWebinar platform. In order to claim credit, you must return to this site (cme-learning.brown.edu) and complete an evaluation to claim and obtain your certificate.
Available Credit
- 1.00 AMA PRA Category 1 Credit™The Warren Alpert Medical School of Brown University is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
- 1.00 AttendanceParticipants will receive a Certificate of Attendance stating this program is designated for AMA PRA Category 1 Credit™. This credit is accepted by the AAPA and AANP.
Price
Live Webinar on June 10, 2021 at 3:00 PM ET
This webcast is hosted via the GoToWebinar platform
To register for this webcast on advances in the treatment of tics please click here